The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and
as a diagnostic and decision making tool in the management prostate cancer patients.The
primary endpoints of the study are the incidence of adverse events (AE) in the study
population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA
PET/CT vs CT on a per-patient and per-lesion basis.